Xyla, 20 mg/ml solution for injection for cattle, horses, dogs and cats

Authorised

• Xylazine hydrochloride

Product identification

Medicine name:

Xyla, 20 mg/ml solution for injection for cattle, horses, dogs and cats Xyla, 20 mg/ml süstelahus veistele, hobustele, koertele ja kassidele

Active substance:

Xylazine hydrochloride

Target species:	
Cattle	
Horse	
Dog	
Cat	

Route of administration:

Intravenous use Intramuscular use Subcutaneous use

Product details

Active substance and strength:

Pharmaceutical form:

Solution for injection

Withdrawal period by route of administration:

Intravenous use:

- Cattle
 - Meat and offal. 1 day
 - Milk. 0 hour
- . Horse
 - Meat and offal. 1 day
 - Milk. 0 hour

. Dog

Intramuscular use:

- Cattle
 - Meat and offal. 1 day
 - Milk. 0 hour
- . Dog
- . Cat

Subcutaneous use:

• Cat

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QN05CM92

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Estonia

Package description:

50 ml clear, type II glass bottle, closed with a bromobutyl rubber stopper and secured with an aluminium cap. Package size: 5x50 ml in a cardboard box.

50 ml clear, type II glass bottle, closed with a bromobutyl rubber stopper and secured with an aluminium cap. Package size: 1x50 ml in a cardboard box.

Additional information

Entitlement type: Marketing Authorisation

Legal basis of product authorisation: Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Interchemie Werken De Adelaar Eesti AS

Marketing authorisation date:

24/09/2019

Manufacturing sites for batch release:

Interchemie Werken De Adelaar Eesti AS

Responsible authority:

State Agency Of Medicines

Authorisation number: 2205

Date of authorisation status change: 24/09/2019

Reference member state:

Estonia

Procedure number: EE/V/0105/001

Concerned member states:

Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Finland France

Germany Greece Hungary Iceland Ireland Italy Latvia Malta Netherlands Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

English (PDF) Published on: 7/12/2021 Download

Source URL: *https://medicines.health.europa.eu/veterinary/60000027438*